Zobrazeno 1 - 10
of 20
pro vyhledávání: '"MESH: Antiviral Agents / therapeutic use"'
Autor:
Marc Hazzan, Sébastien Dharancy, Christophe Legendre, Hélène Fontaine, Alain Duhamel, Nassim Kamar, Benjamin Legendre, Stanislas Pol, Corinne Antoine, Philippe Mathurin, Alexandre Louvet, Laurent Alric, Julien Labreuche
Publikováno v:
Journal of Hepatology
Journal of Hepatology, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, Elsevier, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
Journal of Hepatology, Elsevier, 2019, 70 (5), pp.831-838. ⟨10.1016/j.jhep.2018.12.036⟩
International audience; Background & aims: Before antiviral therapy, kidney transplant recipients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) had poor outcomes. Since the 90s, nucleos(t)ide analogues have been widely used in HBV-
Autor:
Lionel Piroth, Bruno Mourvillier, Joy Mootien, François-Xavier Lescure, Emmanuel Faure, S. Gallien, Dominique Costagliola, Jean-Christophe Richard, Noemie Mercier, Florent Wallet, Yazdan Yazdanpanah, Marion Noret, Claire Andrejak, Jean-Philippe Lanoix, Julien Poissy, Johan Courjon, Saad Nseir, François Danion, Violaine Tolsma, Alain Makinson, Odile Launay, Raphaël Clere-Jehl, Bruno Lina, Drifa Belhadi, Valérie Pourcher, Antoine Kimmoun, Karine Lacombe, Juliette Saillard, Maude Bouscambert-Duchamp, Stéphane Jauréguiberry, Charles Burdet, Toni Alfaiate, Olivier Epaulard, Minh Patrick Lê, Gilles Peytavin, Elisabeth Botelho-Nevers, Thérèse Staub, Guillaume Martin-Blondel, Alpha Diallo, Lila Bouadma, Aline Dechanet, François Goehringer, Florence Ader, Nathan Peiffer-Smadja, Jean-Christophe Navellou, Christelle Delmas, Rostane Gaci, Kevin Bouiller, Maya Hites, André Cabié, Jean Reuter, Sylvie Leroy, Axelle Dupont, François Raffi, Amandine Gagneux-Brunon, Jean Reignier, Clément Dubost
Publikováno v:
Clinical Microbiology and Infection
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
International audience; Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a8dd207add00814d32d637b7eef3ab
https://hal.archives-ouvertes.fr/hal-03364426
https://hal.archives-ouvertes.fr/hal-03364426
Autor:
Delphine Sterlin, Guy Gorochov
Publikováno v:
Pharmacology
Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9a12b1182e8d150ab11b2aa001c856
https://hal.sorbonne-universite.fr/hal-03139698
https://hal.sorbonne-universite.fr/hal-03139698
Autor:
Caroline Solas, E. Meriglier, Stéphane Bouchet, Françoise Stanke-Labesque, Elodie Gautier-Veyret, Carole Schwebel, Peggy Gandia, Zoubir Djerada, Olivier Epaulard, Guillaume Martin-Blondel, Stéphanie Ruiz, Didier Concordet, Fabrice Bonnet, Bruno Mourvillier
Publikováno v:
Clinical Pharmacology & Therapeutics
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩
Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩
Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩
Boffito et al. recalled the critical importance to correctly interpret protein binding. Changes of lopinavir pharmacokinetics in coronavirus disease 2019 (COVID-19) are a perfect illustration. Indeed, several studies described that total lopinavir pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97f4bd4d018c78cd6f5d100aaabd7f9
http://hdl.handle.net/20.500.12278/26884
http://hdl.handle.net/20.500.12278/26884
Autor:
Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(5), 1204-1211. Oxford University Press
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
United States
Clinical Infectious Diseases, 71(5), 1204-1211. Oxford University Press
Clinical Infectious Diseases, Oxford University Press (OUP), 2019, ⟨10.1093/cid/ciz953⟩
Clinical Infectious Diseases, 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(5), 1204-1211. Oxford University Press
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
United States
Clinical Infectious Diseases, 71(5), 1204-1211. Oxford University Press
Clinical Infectious Diseases, Oxford University Press (OUP), 2019, ⟨10.1093/cid/ciz953⟩
Clinical Infectious Diseases, 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9291b965e91f3ecf369fd895a0047810
https://hal-amu.archives-ouvertes.fr/hal-02465266
https://hal-amu.archives-ouvertes.fr/hal-02465266
Autor:
Vincent Minville, Guillaume Martin-Blondel, Jacques Izopet, Stein Silva Sifontes, Rosine Guimbaud, Stéphanie Ruiz, Karen Delavigne, Didier Concordet, Pierre Delobel, Grégory Pugnet, Marlène Murris, Stanilas Faguer, Bernard Georges, Jean-Michel Mansuy, Véronigue Duhalde, Peggy Gandia, Jean-Marie Conil, Yves Rolland, Frédéric Eyvrard
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (11), pp.2962-2964. ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, ⟨10.1093/cid/ciaa558⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (11), pp.2962-2964. ⟨10.1093/cid/ciaa558⟩
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d888ada4af45710e3a7a8801b9bc028
https://hal.archives-ouvertes.fr/hal-03010371
https://hal.archives-ouvertes.fr/hal-03010371
Autor:
Lamazou, F., Oger, P., Dieli-Crimi, Romina, Guerin, A., Letouzey, V., Octernaud, S., Place, V., Calès, P., Descamps, P., Delaroche, L., Universitat Autònoma de Barcelona
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Infectious Diseases, BioMed Central, 2020, 20, pp.845. ⟨10.1186/s12879-020-05551-0⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Infectious Diseases, BioMed Central, 2020, 20, pp.845. ⟨10.1186/s12879-020-05551-0⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Background In December 2019, a new disease (COVID-19) caused by a novel coronavirus called SARS-CoV-2 emerged in China and spread to many other countries. There is only limited data about the clinical features of COVID-19 during pregnancy, especially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155715d3817069f47fe66d607a7f93e2
https://ddd.uab.cat/record/253096
https://ddd.uab.cat/record/253096
Autor:
Sébastien Lhomme, Laurent Alric, Laurence Lavayssière, Florence Abravanel, Jacques Izopet, Nassim Kamar, Arnaud Del Bello, Julie Belliere
Publikováno v:
Transplant Infectious Disease
Transplant Infectious Disease, Wiley, 2019, 21 (4), ⟨10.1111/tid.13093⟩
Transplant Infectious Disease, 2019, 21 (4), pp.e13093. ⟨10.1111/tid.13093⟩
Transplant Infectious Disease, Wiley, 2019, 21 (4), ⟨10.1111/tid.13093⟩
Transplant Infectious Disease, 2019, 21 (4), pp.e13093. ⟨10.1111/tid.13093⟩
International audience; Background and aims: It has been recently suggested that occult hepatitis C virus (HCV) infection and hepatitis E virus (HEV) reactivation might occur after direct acting antiviral agent-induced (DAA-induced) sustained virolog
Autor:
Pischke, Sven, Peron, Jean-Marie, von Wulffen, Moritz, von Felden, Johann, Höner zu Siederdissen, Christoph, Fournier, Sophie, Lütgehetmann, Marc, Iking-Konert, Christoph, Bettinger, Dominik, Par, Gabriella, Thimme, Robert, Cantagrel, Alain, Lohse, Ansgar, Wedemeyer, Heiner, de Man, Robert, Mallet, Vincent
Publikováno v:
Viruses
Viruses, 2019, 11 (2), pp.186. ⟨10.3390/v11020186⟩
Viruses, 2019, 11 (2), pp.186. ⟨10.3390/v11020186⟩
International audience; Objectives: Hepatitis E virus (HEV) infection is a pandemic with regional outbreaks, including in industrialized countries. HEV infection is usually self-limiting but can progress to chronic hepatitis E in transplant recipient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1398::a8a9ecf477e1ff76e5b71569df9798af
https://ut3-toulouseinp.hal.science/hal-03597418/document
https://ut3-toulouseinp.hal.science/hal-03597418/document
Autor:
Nassim Kamar, Laurence Lavayssière, Anne Laure Hebral, Olivier Marion, Jacques Izopet, Olivier Cointault, Laure Esposito, Sébastien Lhomme, David Ribes, Arnaud Del Bello, Florence Abravanel
Publikováno v:
Journal of Hepatology
Journal of Hepatology, 2019, 70 (1), pp.206-214. ⟨10.1016/j.jhep.2018.09.011⟩
Journal of Hepatology, 2019, 70 (1), pp.206-214. ⟨10.1016/j.jhep.2018.09.011⟩
International audience; Hepatitis E virus genotype 3 (HEV3) and 4 (HEV4) can progress to chronic hepatitis in immunosuppressed patients.1 Ribavirin therapy has been shown to be efficient for treating chronic HEV infection in solid-organ-transplant re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fefcd9d62ea9f71744877fdd80ee07
https://ut3-toulouseinp.hal.science/hal-03602075
https://ut3-toulouseinp.hal.science/hal-03602075